Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab

Ukyo Kondo, Taku Kikuchi, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Haruka Sawada, Kota Sato, Tomomi Takaei, Mizuki Ogura, Yu Abe, Osamu Hosoya, Tadao Ishida, Nobuhiro Tsukada

Blood (2025) 146 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2025-5753

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

An open-label rollover study to assess the long-term safety of ixazomib

Sebastian Grosicki, Markus Hansson, Meletios Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee-Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson

Blood (2025) 146 (Supplement 1): 7547.

https://doi.org/10.1182/blood-2025-7547

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Urvi A. Shah

Blood (2024) 144 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2024-201568

Published: 2024

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis

Kodai Kunisada, Taku Kikuchi, Nobuhiro Tsukada, Tomomi Takei, Moe Yogo, Kota Sato, Mizuki Ogura, Yu ABE, Kenshi Suzuki, Tadao Ishida

Blood (2024) 144 (Supplement 1): 3292.

https://doi.org/10.1182/blood-2024-193700

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Moe Yogo, Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Yuki Okda, Kota Sato, Mizuki Ogura, Tomomi Takei, Yu ABE, Kenshi Suzuki, Tadao Ishida

Blood (2023) 142 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2023-174725

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Blood (2023) 142 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2023-174477

Published: 2023

Journal Articles

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Shinsuke Iida, Asuka Mori, Chika Sakai, Kenichi Kato, David Bin-Chia Wu, DaeYoung Yu, Shota Nemoto, Yasuho Yamashita, Takuma Shibahara

Blood (2023) 142 (Supplement 1): 6665.

https://doi.org/10.1182/blood-2023-172849

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz

Blood (2023) 142 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2023-182141

Published: 2023

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Junichiro Nashimoto, Moe Nomura, Hirofumi Irita, Kota Sato, MDPhD, Kanji Miyazaki, MDPhD, Mizuki Ogura, MDPhD, Yu Abe, MD, Nobuhiro Tsukada, MDPhD, Tadao Ishida, MDPhD, Kenshi Suzuki, MD PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-142362

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

An open-label rollover study to assess the long-term safety of ixazomib

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only